GLPwatch
[Cardiovascular Effects of Antidiabetic Therapies].
Dtsch Med Wochenschr · 2017
Last updated 2026-05-28Research suggests that some diabetes medications may affect heart health differently. Metformin appears to have positive effects on the heart, while insulin and certain DPP4-inhibitors (Saxagliptin, Sitagliptin, Alogliptin) seem to have no clear impact. Among GLP-1 drugs, Lixisenatide shows no effect on heart outcomes, but Liraglutide and Semaglutide may reduce heart-related issues. The SGLT2-inhibitor Empagliflozin is linked to lower heart-related death, overall death, and fewer hospitalizations for heart failure.
AI summary of the abstract below.
| Journal | Dtsch Med Wochenschr, 2017 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Cardiovascular Risk Reduction |
Abstract
Type 2- diabetes mellitus (T2DM) represents a major risk factor for cardiovascular complications and mortality. Strict glucose control in the early course of the disease prevents cardiovascular complications only in the long run. Non-medical therapies (diet, exercise, body weight reduction) bear little evidence for positive cardiovascular effects.Bariatric surgery is not number one choice in therapy of T2DM. Metformin seems to provide positive cardiovascular effects. Insulin seems to be cardiovascular neutral, as well as the DPP4-inhibitors Saxagliptin, Sitagliptin and Alogliptin. Concerning GLP-1-RAs, Lixisenatide has a neutral cardiovascular effect, whereas Liraglutide and Semaglutide reduce cardiovascular outcomes. The SGLT2-inhibitor Empagliflozin reduces cardiovascular mortality, total mortality and hospitalization by heart failure.
Verbatim abstract via PubMed 28514822 ↗